more

Cara Therapeutics (CARA)

(Real Time Quote from BATS)

$0.26 USD

-0.01 (-1.89%)

Updated Oct 17, 2024 12:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on November 06,2018

Cara (CARA) delivered earnings and revenue surprises of -10.87% and 7.34%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CARANegative Net Change

The Zacks Analyst Blog Highlights: Diageo, Constellation Brands, Cara, Cronos and GW

by Zacks Equity Research Published on September 14,2018

The Zacks Analyst Blog Highlights: Diageo, Constellation Brands, Cara, Cronos and GW

ETFs & Stocks to Tap Marijuana Boom

by Sweta Killa Published on September 13,2018

Investors seeking to tap the ongoing green rush may consider these ETFs and stocks.

Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on August 07,2018

Cara (CARA) delivered earnings and revenue surprises of -4.00% and 359.84%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

CARANegative Net Change

Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More

by Zacks Equity Research Published on July 05,2018

Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.

Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options

by Zacks Equity Research Published on June 19,2018

Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.

CARANegative Net Change

Surging Earnings Estimates Signal Good News for Cara Therapeutics (CARA)

by Zacks Equity Research Published on September 05,2017

Cara Therapeutics (CARA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.

CARANegative Net Change

Here's Why Cara Therapeutics (CARA) Shares Plummeted 31% Today

by Megan Sanks Published on June 30,2017

Shares of Cara Therapeutics (CARA) nosedived 31% Friday in morning trading after the company announced disappointing results on the CR845 oral medication from a phase 2b trial.